46. Malignant rheumatoid arthritis Clinical trials / Disease details


Clinical trials : 4,325 Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-000710-42-NL
(EUCTR)
15/03/202108/03/2021Research into the effect of the COVID-vaccine in patients who are treated with rituximab (RTX-COVAC study)The RTX-COVAC study: humoral response to COVID-19 vaccination after rituximab, and relation with dose and vaccination timing. A prospective cohort study. - RTX-COVAC Rheumatoid arthritis
MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Trade Name: Comirnaty
Trade Name: COVID-19 Vaccine Moderna
Product Name: COVID-19 Vaccine Moderna
Trade Name: COVID-19 Vaccine AstraZeneca
Product Name: COVID-19 Vaccine AstraZeneca
Sint MaartenskliniekNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
270Phase 4Netherlands
2EUCTR2021-000880-63-SE
(EUCTR)
11/03/202123/02/2021COVID-19 vaccine in patients with rheumatic diseases: The impact of treatments on the vaccine response protection against infection (COVID19-REUMA)COVID-19 vaccine in patients with inflammatory rheumatic diseases: The impact of immunomodulating treatments on the antibody response, T cells response and protection against infection (COVID19-REUMA) - COVID19-REUMA rheumatoid arthritis, SLE, systemic vasculitis, systemic sclerosis, spondylarthritis;Therapeutic area: Body processes [G] - Immune system processes [G12]Trade Name: Comirnaty
Product Name: Comirnaty
INN or Proposed INN: COVID-19 mRNA vaccine (nucleoside-modified)
Other descriptive name: COVID-19 mRNA vaccine (nucleoside-modified)
Trade Name: COVID-19 Vaccine AstraZeneca
Product Name: COVID-19 Vaccine AstraZeneca
INN or Proposed INN: COVID-19 Vaccine (ChAdOx1-S [recombinant])
Other descriptive name: COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19)
Trade Name: COVID-19 Vaccine Moderna
Product Name: COVID-19 Vaccine Moderna
INN or Proposed INN: COVID-19 mRNA Vaccine (nucleoside modified)
Other descriptive name: COVID-19 mRNA vaccine Moderna (CX-024414)
Skåne University Hospital, department of rheumatology in Lud and MalmöNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
868Phase 4Sweden